Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Cyclophosphamide

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01265849Phase 3Completed

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Showing all 1 trials

Research Network

Common Treatments

  • Cyclophosphamide1
  • Li1
  • Radiotherapy1
  • Zinc1
  • Cisplatin1

Active Sponsors

  • Teva Branded Pharmaceutical Products R&D, Inc.1
  • CEL-SCI Corporation1
  • Orient Europharma Co., Ltd.1

Top Investigators

Related Conditions

  • Squamous Cell Carcinoma Of The Oral Cavity1

Activity Timeline